ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ITCI Company Profile and Key Details

NASDAQ : ITCI

Intra-Cellular Therapies, Inc.

$131.24

-0.01-0.01%

At Close 4:00 PM

67.83

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

ITCI Stock Price Chart

Stock Price Today

Intra-Cellular Therapies, Inc. (ITCI) stock declined over -0.01%, trading at $131.24 on NASDAQ, down from the previous close of $131.25. The stock opened at $131.24, fluctuating between $131.23 and $131.37 in the recent session.

Stock Snapshot

131.25

Prev. Close

131.24

Open

13.95B

Market Cap

106.33M

Number of Shares

131.23

Day Low

131.37

Day High

-182.28

P/E Ratio

97.33%

Free Float in %

-0.72

EPS (TTM)

6.14

Book Value

-1.29

Cash Flow per Share

3.18M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 11, 2025	131.24	131.37	131.23	131.25	3.18M
Mar 10, 2025	131.21	131.28	131.20	131.25	2.62M
Mar 07, 2025	131.30	131.32	131.21	131.24	1.26M
Mar 06, 2025	131.23	131.28	131.20	131.25	1.16M
Mar 05, 2025	131.28	131.35	131.18	131.19	2.87M
Mar 04, 2025	131.26	131.36	131.21	131.24	2.91M
Mar 03, 2025	131.33	131.35	131.20	131.28	7.16M
Feb 28, 2025	128.49	128.50	128.06	128.20	1.49M
Feb 27, 2025	128.59	128.63	128.20	128.25	1.28M
Feb 26, 2025	129.00	129.00	128.04	128.46	1.6M
Feb 25, 2025	128.58	128.74	128.31	128.58	1.46M
Feb 24, 2025	128.68	128.72	128.53	128.57	1.73M
Feb 21, 2025	128.77	128.77	128.52	128.60	1.26M
Feb 20, 2025	128.68	128.77	128.47	128.54	1.46M
Feb 19, 2025	128.03	128.75	128.00	128.55	2.18M
Feb 18, 2025	128.00	128.13	127.91	127.96	1.82M
Feb 14, 2025	127.95	128.19	127.80	127.82	1.38M
Feb 13, 2025	127.91	128.15	127.72	128.06	1.63M
Feb 12, 2025	127.50	127.99	127.45	127.97	2.47M
Feb 11, 2025	127.22	127.97	127.06	127.56	1.57M

Contact Details

New York, NY 10016

United States

Website: https://www.intracellulartherapies.comContact: 646 440 9333

About Company

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Frequently Asked Questions

What is the current Intra-Cellular Therapies, Inc. (ITCI) stock price?

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) stock price is $131.24 in the last trading session. During the trading session, ITCI stock reached the peak price of $131.37 while $131.23 was the lowest point it dropped to. The percentage change in ITCI stock occurred in the recent session was -0.01% while the dollar amount for the price change in ITCI stock was -$0.01.

ITCI's industry and sector of operation?

The NASDAQ listed ITCI is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Intra-Cellular Therapies, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ITCI?

Dr. Robert E. Davis Ph.D.
Senior Vice President & Chief Scientific Officer
Ms. Karen Patruno Sheehy Esq.
Senior Vice President & Chief Compliance Officer
Dr. Michael Olchaskey
Senior Vice President & Head of Regulatory Affairs
Mr. Mark Neumann
EVice President & Chief Commercial Officer
Mr. Juan Fernando Sanchez
Vice President of Corporation Communications & Investor Relations
Mr. Lawrence J. Hineline CPA, CPA
Senior Vice President of Fin., Chief Financial Officer, Treasurer & Assistant Sec.
Mr. John A. Bardi
Senior Vice President of Market Access, Policy & Gov. Affairs
Dr. Sharon Mates Ph.D.
Co-Founder, Chairman, Chief Executive Officer & Pres
Mr. Michael I. Halstead J.D.
Executive Vice President, Gen. Counsel & Sec.
Dr. Suresh K. Durgam M.D.
Executive Vice President & Chief Medical Officer

How ITCI did perform over past 52-week?

ITCI's closing price is 107.33% higher than its 52-week low of $63.30 where as its distance from 52-week high of $131.37 is -0.1%.

How many employees does ITCI have?

Number of ITCI employees currently stands at 860.

Link for ITCI official website?

Official Website of ITCI is: https://www.intracellulartherapies.com

How do I contact ITCI?

ITCI could be contacted at phone 646 440 9333 and can also be accessed through its website. ITCI operates from 430 East 29th Street, New York, NY 10016, United States.

How many shares of ITCI are traded daily?

ITCI stock volume for the day was 3.18M shares. The average number of ITCI shares traded daily for last 3 months was 3.06M.

What is the market cap of ITCI currently?

The market value of ITCI currently stands at $13.95B with its latest stock price at $131.24 and 106.33M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	860
Beta	0.7
Sales or Revenue	$462.18M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic